ILC Dover Acquires KSE Scientific, a Leading Supplier of Water for Injection and Related Solutions for Biopharma, Cell & Gene Therapy, Tissue Banking and Medical Device End-Markets

Frederica, Delaware-  December 16, 2021 – ILC Dover, Inc. (“ILC Dover”, “ILC” or the “Company”), a leading designer and manufacturer of high-performance materials for life critical and primarily life sciences-based applications, today announced the acquisition of KSE Scientific (“KSE”), a sterile solutions manufacturer which specializes in the production of Water for Injection (WFI) and related […]

ILC Dover Appoints Corey Walker as CEO

FREDERICA, Del. & NEW YORK–(BUSINESS WIRE)–ILC Dover announced today that Corey Walker, an experienced executive in life sciences, advanced technologies and applied materials, will join ILC Dover as Chief Executive Officer effective November 15, 2021. Mr. Walker had previously worked closely with New Mountain Capital from 2016 to 2020 while he was a senior executive […]

DoverPac® for HPAPI Transfers: Superior Powder Flow & Zero Cleaning

In a recent webinar, DoverPac® for HPAPI Transfers, ILC Dover discussed the two key benefits of DoverPac® technology: superior powder flow properties and zero cleaning. DoverPac® technology is a containment system that does a lot more than transfer powders. DoverPac® was purposely designed for ease of use in handling pharmaceutical products and should not be […]

[Webinar] DoverPac HPAPI Transfers: Zero Cleaning and Superior Powder Flow

This presentation of the DoverPac FIBC high containment system for transferring powders describes the unique capabilities in pharmaceutical processes. The DoverPac virtually eliminates cleaning resulting in cost savings and production time efficiencies. The benefits of the flexible wall technology is proven to be the best when filling and discharging poor flowing powders while promoting mass […]

[Webinar] ILC Dover’s NEW Aseptic Isolator System – soloPURE™

With the development of ILC Dover’s new Aseptic Isolator system new opportunities have opened up for many organizations who were previously able to conduct fill finish activities due to facility restraints or expensive closed barrier systems.  This new technology also allows existing facilities to handle different product previously thought to be ‘out of reach’ in […]

ILC Dover Defines the Future of Sterile Manufacturing with the soloPURE™ Flexible Aseptic Isolator

NEWARK, Del., April 13, 2021  — ILC Dover LP (“ILC Dover” or the “Company”), specializing in the innovative design and production of single-use flexible solutions for global pharmaceutical and biopharmaceutical processing, today introduced the soloPURE™ flexible aseptic isolator, a cost-effective, closed-barrier system for sterile manufacturing. With a fully disposable, single-use chamber and a CAPEX-efficient compact […]

[Whitepaper] ADC and Highly Potent Substance Containment

Solo Containment’s Martyn Ryder has been observing environmental monitoring systems from as early as 1989. It was clear from the start that segregation between operators and API powder was the key to reducing occupational exposure. In Ryder’s work, he grasped the importance of maintaining long-term and repeatable safety standards within the pharmaceutical sector. As a […]

[Whitepaper] Development of a Disposable Grade-A Aseptic Fill/Finish Isolation System

Isolation of aseptic processes is not a new technology. Rigid stainless-steel isolators have been available for decades, and flexible film isolation has been used in aseptic processing since the 1970s. Still, these systems tended to be a composite of stainless-steel chambers and airflow modules with a flexible film user interface. Solo Containment (now part of […]

Driving Expansion, ILC Dover Appoints New President in Pharmaceutical / Biopharmaceutical Business Unit

Frederica, Delaware, December 9, 2020 –  ILC Dover, a world leader in the design and production of single-use flexible solutions for pharmaceutical and biopharmaceutical manufacturing, today named David Radspinner as President of the Pharmaceutical/Biopharmaceutical Business Unit, effective December 14, 2020. In his new role, Dr. Radspinner is expected to contribute to ILC Dover’s continued growth by building and […]